Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
'Hidden' factors influencing quality of life in patients with multiple sclerosis.
Cognitive impairment in relapsing remitting and secondary progressive multiple sclerosis patients: efficacy of a computerized cognitive screening battery.
Pain in multiple sclerosis: A systematic review of neuroimaging studies.
Morning glory syndrome associated with multiple sclerosis.
New Approaches in the Design and Development of Cannabinoid Receptor Ligands: Multifunctional and Bivalent Compounds.
The role of IFNβ in the treatment of MSand EAE - In the perspective of inflammasomes.
Multiple sclerosis: Linking disability and spinal cord imaging outcomes in MS.
Measurement and treatment of imbalance and fall risk in multiple sclerosis using the international classification of functioning, disability and health model.
Pilot study of minocycline in relapsing-remitting multiple sclerosis.
Phosphodiesterase 5 inhibition at disease onset prevents experimental autoimmune encephalomyelitis progression through immunoregulatory and neuroprotective actions.
Multiple Sclerosis: Risk Factors and Their Interactions.
Bone health and multiple sclerosis.
Dalfampridine: A Medication to Improve Walking in Patients with Multiple Sclerosis (July/August).
Synthesis and biological evaluation of tyrosine modified analogues of the α4β7 integrin inhibitor biotin-R(8)ERY.
A comparative analysis of Patient-Reported Expanded Disability Status Scale tools.
Co-Delivery of Autoantigen and B7 Pathway Modulators Suppresses Experimental Autoimmune Encephalomyelitis.
Ultrasonographic evaluation of cerebral arterial and venous haemodynamics in multiple sclerosis: a case-control study.
Associations between Proprioceptive Neural Pathway Structural Connectivity and Balance in People with Multiple Sclerosis.
Progressive multiple sclerosis exhibits decreasing glutamate and glutamine over two years.
XY sex chromosome complement, compared with XX, in the CNS confers greater neurodegeneration during experimental autoimmune encephalomyelitis
Epstein-Barr virus and Mycobacterium avium subsp. paratuberculosis peptides are cross recognized by anti-myelin basic protein antibodies in multiple sclerosis patients.
Prenatal vitamin d deficiency induces an early and more severe experimental autoimmune encephalomyelitis in the second generation.
Treatment with interferon-beta does not induce anti-nuclear and anti-neuronal serum autoantibodies in multiple sclerosis patients.
[The chronic form of tick-born encephalitis with a clinical manifestation of disseminated encephalomyelitis (case description).]
SIRT1 activating compounds reduce oxidative stress and prevent cell death in neuronal cells.
Pages
« first
‹ previous
…
298
299
300
301
302
303
304
305
306
…
next ›
last »